

SAVE THE DATE



Salzburg
Cancer
Research
Institute

4th SALZBURG BREAST CANCER TALK 23. – 24.10.2020

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 23rd OCTOBER

12:30 – 13:30	Welcome & Business Lunch	
13:30–13:35	Introduction	Richard Greil (<i>Salzburg</i>)
13:35 – 15:15	Section 1 <i>Chair: Richard Greil, Pedro Romero</i>	
13:35– 14:25	The Clinical Point of View	
13:35	Oxford-style debate: Immunotherapy in breast cancer: failure or magic bullet?	Simon P. Gampenrieder (<i>Salzburg</i>) pro Gabriel Rinnerthaler (<i>Salzburg</i>) contra
14:00	Predictive biomarkers in breast cancer immunotherapy trials	Luca Gianni (<i>Milan</i>)
14:25 – 15:15	Metabolism and Metabolomics	
14:25	Hypoxia-inducible metabolites shape T cell fate	Iosifina Foskolou (<i>Cambridge</i>)
14:50	Navigating metabolic pathways to enhance antitumor immunity and immunotherapy	Pedro Romero (<i>Lausanne</i>)
15:15 – 15:45	Coffee Break	
15:45 – 18:30	Section 2 <i>Chair: Fritz Aberger, Simon P. Gampenrieder</i>	
15:45 – 16:35	Influence on Immunogenicity	
15:45	... by sex hormones	Berna C. Özdemir (<i>Lausanne</i>)
16:10	... epigenetic regulation	Onur Boyman (<i>Zurich</i>)
16:35 – 17:25	The Innate Immune System	
16:35	Innate Immunity, inflammation and cancer: double edged swords	Alberto Mantovani (<i>Milan</i>)
17:00	Pharmacological re-programming of CD144 pro-metastatic monocytes in human breast cancer	Marie-Agnes Doucey (<i>Lausanne</i>)
17:30 – 18:30	Panel Discussion <i>Chair: Richard Greil</i>	Gianni, Foskolou, Romero, Özdemir, Boyman, Mantovani, Doucey
19:00	Dinner	

SATURDAY, 24th OCTOBER

08:30 – 10:00	The Adaptive Immune System <i>Chair: Barbara Seliger, Gabriel Rinnerthaler</i>	
08:30	PD-L1 vs. TILs: analytic and diagnostic issues*	Roberto Salgado (<i>Antwerp</i>)
09:00	Tertiary lymphoid structures: Phenotypic, genotypic and functional features and their link with the response to cancer immunotherapy*	Karen Willard-Gallo (<i>Brussels</i>)
09:30	MHC class I loss in breast cancer*	Barbara Seliger (<i>Halle</i>)
10:00 – 10:30	Coffee Break	
10:30 – 12:10	New Treatment Strategies <i>Chair: Richard Greil, Giuseppe Curigliano</i>	
10:30	Immunotherapy strategies beyond PD1/PD-L1 inhibition	Giuseppe Curigliano (<i>Milan</i>)
10:55	Bispecific antibodies in the treatment of solid tumors	Marco Gerlinger (<i>London</i>)
11:20	Adoptive T cell therapy for metastatic melanoma: Lessons learned and implications for breast cancer	Laszlo G. Radvanyi (<i>Toronto</i>)
11:45	CAR T-Cells in breast cancer	John Maher (<i>London</i>)
12:10 – 12:55	Panel Discussion <i>Chair: Richard Greil</i>	Curigliano, Gerlinger, Radvanyi, Maher
12:55	Closing remarks	Richard Greil (<i>Salzburg</i>)
13:00 – 14:00	Business Lunch & Farewell	

* Discussion after lecture

The Pitter Event Center
Rainerstrasse 6 – 8
5020 Salzburg

www.imlauer.com



Free WLAN-Access:
Pitter Event Center
PW: pitter20



Prof. Dr. Richard Greil
Head of the IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Pedro Romero MD
Associate Director, Department of Fundamental Oncology
Lausanne University Hospital (CHUV)
Faculty of Biology and Medicine
University of Lausanne
Ludwig Institute for Cancer Research, Lausanne Branch
Lausanne, Switzerland

Dr. Gabriel Rinnerthaler
IIIrd Medical Department, University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Dr. Simon P. Gampenrieder
IIIrd Medical Department, University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Luca Gianni MD
Michelangelo Foundation
Milan, Italy

Dr. Iosifina Foskolou
Prof. R. Johnson's Group
Evelyn Trust Patrick Sissons Fellow
Darwin College, Cambridge, United Kingdom
Jonas Söderquists Scholar, Karolinska Institutet
Stockholm, Sweden

Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research
Lab Department of Molecular Biology
University of Salzburg
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Berna Özdemir MD PhD
Department of Oncology, Lausanne University Hospital
Lausanne, Switzerland

Prof. Onur Boyman MD
Chair of Clinical Immunology
Deputy Dean of Faculty of Medicine
University of Zurich
Director, Department of Immunology
University Hospital Zurich
Zurich, Switzerland

Prof. Alberto Mantovani MD
Scientific Director, Istituto Clinico Humanitas IRCCS
Humanitas University, Milan, Italy
Chair of Inflammation and Therapeutic Innovation
William Harvey Research Institute, London, United Kingdom

Marie-Agnès Doucey PhD MER
Project Leader, Department of Oncology UNIL CHUV
Ludwig Institute for Cancer Research, Lausanne Branch
Ichnos Sciences SA
Lausanne, Switzerland

Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology
Martin Luther University, Medical Faculty
Halle, Germany

Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Antwerp, Belgium
Division of Research, Peter Mac Callum Cancer Center
Melbourne, Australia

Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Prof. Giuseppe Curigliano MD PhD
Clinical Director, Early Drug Development for
Innovative Therapy
Co-Chair Cancer Experimental Therapeutics Program
Department of Oncology and Hemato-Oncology
University of Milan, European Institute of Oncology
Milan, Italy

Marco Gerlinger MD FRCP
Medical Oncologist and Research Group Leader
Translational Oncogenomics Laboratory
Centre for Evolution and Cancer
Institute of Cancer Research
London, United Kingdom

Dr. Laszlo G. Radvanyi PhD
President and Scientific Director
Ontario Institute for Cancer Research
Toronto, Ontario, Canada

Dr. John Maher
Consultant and Senior Lecturer in Immunology
King's College London
London, United Kingdom



Organization:

Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with
Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
www.limcr.at and
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
www.cccit.at

in cooperation with the
Cancer Cluster Salzburg | www.cancercluster-salzburg.at and AGMT gemeinnützige GmbH | www.agmt.at

endorsed by
ECCO: European CanCER Organisation



Kindly supported by:



This event is requested for
8 CME credits (ECMEC®s)